Loading
Treatment Resistant Depression / ZAP-X / Depressive Disorder · Interventional Study
ClinicalTrials.gov · August 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a completed, uncontrolled single-arm trial of stereotactic radiotherapy (ZAP-X device) for treatment-resistant depression in 9 participants. The registry record describes the study design and primary outcome measure (MADRS change at 4 weeks post-treatment) but contains no efficacy, safety, or outcome data. No conclusions about clinical benefit can be drawn from this registration alone.
Interventional, Randomized, Parallel, Double masking, Treatment purpose. Treatment-Resistant Depression, Depressive Disorder; age from 18 Years; to 50 Years. Intervention: Intervention Group: 15Gy; Intervention Group: 20Gy; Intervention Group: 25 Gy. n = 9. 1 site: China.
This is a completed, uncontrolled single-arm trial of stereotactic radiotherapy (ZAP-X device) for treatment-resistant depression in 9 participants. The registry record describes the study design and primary outcome measure (MADRS change at 4 weeks post-treatment) but contains no efficacy, safety, or outcome data. No conclusions about clinical benefit can be drawn from this registration alone.
No results are reported in this registry record; outcomes, efficacy, safety data, and statistical significance are not available. No information on patient baseline characteristics, treatment protocol details, adverse events, or dropout rates provided in registry record.
This record documents a planned trial but provides no outcome data. Clinicians cannot use this registry entry to assess whether stereotactic radiotherapy is effective or safe for treatment-resistant depression; results must be published separately.
Small, single-center, uncontrolled interventional study with recruitment completed but no results posted in registry; design and sample size insufficient to support efficacy claims.
As stated by the source record.
Quoted from the source exactly as published.
This record documents a planned trial but provides no outcome data. Clinicians cannot use this registry entry to assess whether stereotactic radiotherapy is effective or safe for treatment-resistant depression; results must be published separately.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07274917). This is a study registration, not published results. Lead sponsor: Capital Medical University. Recruitment status: COMPLETED. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 9 participants (ACTUAL). Conditions: Treatment-Resistant Depression, Depressive Disorder. Interventions: DEVICE: ZAP-X. Primary outcome measures: Change in the Montgomery-Åsberg Depression Rating Scale (MADRS) score at 4 weeks post-treatment compared to baseline , Pre-treatment and 4 weeks post treatment. Brief summary: This study is an clinical trial aimed at evaluating the effectiveness and safety of stereotactic radiotherapy for treatment-resistant depression
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.